Thursday, 17 Aug 2017

You are here

Adalimumab Effective in Pediatric Plaque Psoriasis

Adalimumab is currently FDA approved for use in adult psoriasis, pediatric Crohn's disease and polyarticular juvenile idiopathic arthritis.  The current Lancet trial assesses the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis.

This multicenter, multinational study enrolled 114 children ages 4 to 18 yrs with severe plaque psoriasis and randomized them to treatment with adalimumab (ADA) (0·8 mg/kg or 0·4 mg/kg subcutaneously)every other week after week 1, or oral methotrexate (MTX) once weekly (0·1–0·4 mg/kg) for 16 weeks.

A week 16  PASI75 was achieved moreso with ADA (58%) compared to MTX (32%).

Clearing or minimal psoriasis was seen with 61% of ADA and 41% of the MTX patients.

There were no unexpected toxicities or infections and 3 serious adverse events were reported, all in patients in the adalimumab 0·4 mg/kg group, and were not judged to be related to study drug.

ADA appears to be effective and safe in children with plaque psoriasis. 

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Psoriatic Arthritis Patients with Comorbidities have Worse Disease and Poor Responses

A population-based cohort study shows that comorbidities in psoriatic arthritis patients (PsA) were associated with higher disease activity, shorter persistence and reduced clinical response to TNF inhibitors (TNFi). 

FDA Arthritis Advisory Panel Endorses Tofacitinib Approval for Psoriatic Arthritis

On Thursday, August 3, the FDA Arthritis Advisory Committee (AAC) met to consider tofacitinib for use in patients with psoriatic arthritis. The panel voted 10-1 in favor of approval.

Pediatric Consensus on Comorbidity Assessments

Comorbidity is a serious consequence or confounder in patients with inflammatory diseases. This has been well described in both psoriatic and rheumatoid disease.  JAMA Dermatology has published the recommendations of a pediatric multispecialty group regarding the screening for comorbid disease. (Citation source

Obesity Impairs TNF Inhibitor Responses in Axial Spondyloarthritis

Investigators with the Swiss Clinical Quality Management (SCQM) program have studied the effects of obesity on patients with axial spondyloarthritis (axSpA) and, specifically, their response to tumor necrosis factor inhibitors (TNFi).

FDA Approves Tremfya (guselkumab) for Plaque Psoriasis

The U.S. Food and Drug Administration (FDA) has approved the IL-23 inhibitor, Tremfya (guselkumab), for patients with moderate to severe plaque psoriasis.